The increase in BDNF and TrkB expression following treatment suggests a favorable shift toward neuroprotective and repair-promoting pathways, which may counteract the neurocognitive impairments and behavioral deficits commonly observed in CM survivors. This evidence concerns the gene BDNF and cutaneous mastocytosis.